NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Technical Validation of MR Biomarkers of Obesity-Associated NAFLD
Technical Validation of MR Biomarkers of Obesity-Associated NAFLD

NCT03674528

CompletedN/A

Sponsor: University of Wisconsin, Madison

Conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis

Interventions: Magnetic Resonance Elastography (MRE), Liver biopsy

Countries: United States

The overall goal of this collaborative research program is to develop, validate and translate advanced quantitative magnetic resonance (MR) biomarkers of obesity-associated non-alcoholic fatty liver disease (NAFLD). This protocol represents the research plan for two distinct phases. The first phase is an optimization phase. The second phase is designed to complete a rigorous test of conventional and advanced MRE techniques. Complementary anthropometric, laboratory, and MR measures will also be collected to characterize the cohort and identify factors that affect MRE performance

Eligibility overview

Sex: ALL

Age: 18 Years to

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria (Phase 1 and 2 participants)

* Age of at least 18 years
* Severely obese (BMI ≥ 35 kg/m2) patient

Inclusion Criteria (Phase 2 participants only)

* Cleared for weight-loss surgery
* Willing and able to complete all safety and follow-up procedures
* Willing to allow for the banking of biological samples

Exclusion Criteria (Phase 1 and 2 participants)

* Contraindications to MRI
* Girth or weight that exceeds scanner capacity
* Women of childbearing potential that are pregnant or will be attempting to become pregnant during the study duration.

Exclusion Criteria (Phase 2 participants only)

* Known liver malignancies
* Regular \& excessive alcohol consumption within 2 years prior to recruitment
* Use of steatogenic or hepatotoxic drugs
* Clinical or laboratory evidence of liver disease other than Nonalcoholic fatty liver disease (NAFLD)/ Nonalcoholic steatohepatitis (NASH) (e.g. HCV Ab, HBV Ab, ceruloplasmin)
* The subject has increased bleeding risk (i.e., decreased platelets, von Willebrand disease)
Locations (2)
  • La Jolla, California, United States
  • Madison, Wisconsin, United States